

---

**Product Data Sheet**

---

Product Name: Sultopride (LIN-1418)

Cat. No.: GC31188

**Chemical Properties**

Cas. No. 53583-79-2

SMILES O=C(NCC1N(CC)CCC1)C2=CC(S(=O)(CC)=O)=CC=C2OCFormula  $C_{17}H_{26}N_2O_4S$  M.Wt 354.46

Solubility Soluble in DMSO Storage Store at -20°C

General tips For obtaining a higher solubility , please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.

Structure **Protocol****Animal experiment:**

Thirty-six male Sprague-Dawley rats weighing 180 to 220 g are used in this study. The rats are divided into three groups of 6 each. One group is intraperitoneally injected with Sultopride (100 mg/kg body weight), the second group with sulphide (100 mg/kg body weight), and the third group with normal saline. One hundred minutes after the initial treatments, apomorphine (0.1 mg/kg body weight, dissolved in saline ad libitum) is administered subcutaneously to the three groups, and 20 minutes later the rats are sacrificed. The third group serves as controls[1].

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

---

## Product Data Sheet

---

### References:

[1]. Moriuchi K,  
et al. Differences  
in effects of  
sultopride and  
sulpiride on  
dopamine  
turnover in rat  
brain.  
Neurochem Res.  
1995  
Jan;20(1):95-9.

### Background

Sultopride is a selective antagonist of dopamine D2 receptor.

Sultopride is a selective antagonist of dopamine D2 receptor. DOPAC and HVA levels in the striatum, the nucleus accumbens and the medial prefrontal cortex are higher in the rats treated with Sultopride and sulpiride than those of the controls. In the striatum, DOPAC and HVA levels are higher in the Sultopride-treated rats than the sulpiride-treated rats ( $p < 0.05$ ). In the nucleus accumbens, DOPAC levels are higher in the Sultopride-treated rats than sulpiride treated rats ( $p < 0.05$ ). In the Sultopride-treated rats, DOPAC and HVA levels are higher in the striatum or in the nucleus accumbens than in the medial prefrontal cortex ( $p < 0.05$ )[1].

[1]. Moriuchi K, et al. Differences in effects of sultopride and sulpiride on dopamine turnover in rat brain. Neurochem Res. 1995 Jan;20(1):95-9.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA